ADMA Biologics (ADMA) Stock Forecast, Price Target & Predictions
ADMA Stock Forecast
ADMA Biologics stock forecast is as follows: an average price target of $16.00 (represents a -24.88% downside from ADMA’s last price of $21.30) and a rating consensus of 'Strong Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ADMA Price Target
ADMA Analyst Ratings
Strong Buy
ADMA Biologics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 14, 2024 | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $17.14 | 4.99% | -15.49% |
Jun 20, 2024 | Anthony Petrone | Mizuho Securities | $14.00 | $10.62 | 31.83% | -34.27% |
Jan 03, 2023 | - | H.C. Wainwright | $4.50 | $3.88 | 15.98% | -78.87% |
Nov 10, 2022 | - | Mizuho Securities | $6.00 | $3.05 | 96.68% | -71.83% |
Jul 25, 2022 | - | H.C. Wainwright | $4.00 | $2.17 | 84.33% | -81.22% |
10
ADMA Biologics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 2 |
Avg Price Target | - | $18.00 | $16.00 |
Last Closing Price | $21.30 | $21.30 | $21.30 |
Upside/Downside | -100.00% | -15.49% | -24.88% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 14, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
Oct 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Sep 20, 2024 | Cantor Fitzgerald | Buy | Buy | Hold |
Aug 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jul 09, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
May 10, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
May 10, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Feb 29, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
Feb 29, 2024 | H.C. Wainwright | Buy | Buy | Hold |
10
ADMA Biologics Financial Forecast
ADMA Biologics Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | $67.27M | $60.12M | $56.91M | $49.98M | $41.09M | $33.91M | $29.10M | $26.38M | $20.68M | $17.83M | $16.05M | $13.96M | $10.28M | $7.79M | $10.20M | $12.04M | $7.22M | $6.56M | $3.53M | $4.04M | $2.63M |
Avg Forecast | $129.35M | $125.10M | $117.13M | $112.80M | $113.38M | $105.81M | $86.44M | $77.28M | $72.13M | $62.13M | $55.50M | $51.26M | $46.35M | $34.48M | $31.81M | $25.90M | $21.76M | $18.70M | $16.42M | $14.58M | $12.85M | $9.96M | $10.57M | $11.34M | $10.42M | $5.77M | $4.08M | $3.48M | $3.21M | $2.61M |
High Forecast | $136.95M | $132.45M | $124.01M | $117.28M | $117.75M | $105.83M | $86.44M | $81.81M | $76.36M | $65.77M | $58.76M | $54.27M | $49.08M | $34.48M | $31.81M | $25.90M | $21.76M | $18.70M | $16.42M | $14.58M | $12.85M | $9.96M | $10.57M | $11.34M | $10.42M | $5.77M | $4.08M | $3.48M | $3.86M | $3.14M |
Low Forecast | $123.24M | $119.19M | $111.59M | $108.32M | $109.00M | $105.80M | $86.44M | $73.62M | $68.72M | $59.19M | $52.88M | $48.84M | $44.16M | $34.48M | $31.81M | $25.90M | $21.76M | $18.70M | $16.42M | $14.58M | $12.85M | $9.96M | $10.57M | $11.34M | $10.42M | $5.77M | $4.08M | $3.48M | $2.57M | $2.09M |
# Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 9 |
Surprise % | - | - | - | - | - | - | - | - | - | 1.08% | 1.08% | 1.11% | 1.08% | 1.19% | 1.07% | 1.12% | 1.21% | 1.11% | 1.09% | 1.10% | 1.09% | 1.03% | 0.74% | 0.90% | 1.15% | 1.25% | 1.61% | 1.01% | 1.26% | 1.01% |
Forecast
ADMA Biologics EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 9 |
EBITDA | - | - | - | - | - | - | - | - | - | $8.69M | $2.03M | $-494.49K | $-6.32M | $-7.46M | $-7.47M | $-13.36M | $-11.82M | $-12.99M | $-14.33M | $-13.95M | $-15.07M | $-12.79M | $-16.23M | $-15.74M | $-7.00M | $-7.97M | $-10.33M | $-10.72M | $-15.67M | $-5.80M |
Avg Forecast | $-74.94M | $-72.48M | $-67.86M | $-65.35M | $-65.69M | $-61.31M | $-50.08M | $-7.22M | $-41.79M | $-35.99M | $-32.16M | $-7.72M | $-3.23M | $-19.68M | $-18.16M | $-8.26M | $-12.42M | $-10.67M | $-9.37M | $-14.78M | $-7.33M | $-5.69M | $-6.03M | $-14.52M | $-5.95M | $-3.29M | $-2.33M | $-12.06M | $-11.63M | $-5.77M |
High Forecast | $-71.40M | $-69.06M | $-64.65M | $-62.76M | $-63.15M | $-61.30M | $-50.08M | $-5.78M | $-39.81M | $-34.29M | $-30.64M | $-6.18M | $-2.58M | $-19.68M | $-18.16M | $-6.61M | $-12.42M | $-10.67M | $-9.37M | $-11.82M | $-7.33M | $-5.69M | $-6.03M | $-11.62M | $-5.95M | $-3.29M | $-2.33M | $-9.65M | $-9.30M | $-4.61M |
Low Forecast | $-79.35M | $-76.74M | $-71.85M | $-67.95M | $-68.22M | $-61.31M | $-50.08M | $-8.67M | $-44.24M | $-38.11M | $-34.04M | $-9.27M | $-3.88M | $-19.68M | $-18.16M | $-9.91M | $-12.42M | $-10.67M | $-9.37M | $-17.73M | $-7.33M | $-5.69M | $-6.03M | $-17.42M | $-5.95M | $-3.29M | $-2.33M | $-14.47M | $-13.95M | $-6.92M |
Surprise % | - | - | - | - | - | - | - | - | - | -0.24% | -0.06% | 0.06% | 1.95% | 0.38% | 0.41% | 1.62% | 0.95% | 1.22% | 1.53% | 0.94% | 2.05% | 2.25% | 2.69% | 1.08% | 1.18% | 2.42% | 4.44% | 0.89% | 1.35% | 1.01% |
Forecast
ADMA Biologics Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 9 |
Net Income | - | - | - | - | - | - | - | - | - | $2.57M | $-6.37M | $-12.76M | $-25.93M | $-20.48M | $-18.36M | $-35.20M | $-20.11M | $-20.99M | $-22.23M | $-21.60M | $-21.60M | $-20.03M | $-23.23M | $-21.72M | $-13.30M | $-13.83M | $-15.09M | $-12.93M | $-19.11M | $-7.14M |
Avg Forecast | $50.18M | $45.90M | $41.62M | $38.56M | $37.94M | $31.82M | $19.58M | $-9.02M | $6.12M | $-1.84M | $-6.12M | $-9.65M | $-3.86M | $-18.77M | $-19.37M | $-10.32M | $-22.45M | $-33.50M | $-36.93M | $-19.46M | $-39.96M | $-45.21M | $-38.02M | $-17.75M | $-42.08M | $-51.46M | $-67.51M | $-14.70M | $-13.22M | $-6.50M |
High Forecast | $54.02M | $49.41M | $44.79M | $42.84M | $42.41M | $34.26M | $21.08M | $-7.21M | $9.18M | $-1.72M | $-5.74M | $-7.72M | $-3.09M | $-18.77M | $-19.37M | $-8.25M | $-22.45M | $-33.50M | $-36.93M | $-15.57M | $-39.96M | $-45.21M | $-38.02M | $-14.20M | $-42.08M | $-51.46M | $-67.51M | $-11.76M | $-10.58M | $-5.20M |
Low Forecast | $47.10M | $43.08M | $39.06M | $32.13M | $33.48M | $29.87M | $18.38M | $-10.82M | $3.06M | $-1.98M | $-6.59M | $-11.57M | $-4.64M | $-18.77M | $-19.37M | $-12.38M | $-22.45M | $-33.50M | $-36.93M | $-23.35M | $-39.96M | $-45.21M | $-38.02M | $-21.31M | $-42.08M | $-51.46M | $-67.51M | $-17.64M | $-15.87M | $-7.80M |
Surprise % | - | - | - | - | - | - | - | - | - | -1.40% | 1.04% | 1.32% | 6.71% | 1.09% | 0.95% | 3.41% | 0.90% | 0.63% | 0.60% | 1.11% | 0.54% | 0.44% | 0.61% | 1.22% | 0.32% | 0.27% | 0.22% | 0.88% | 1.45% | 1.10% |
Forecast
ADMA Biologics SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 9 |
SG&A | - | - | - | - | - | - | - | - | - | $14.73M | $14.25M | $14.51M | $13.89M | $12.89M | $11.97M | $13.70M | $11.70M | $10.73M | $10.44M | $10.03M | $9.30M | $9.12M | $8.70M | $7.93M | $7.03M | $7.20M | $6.09M | $5.60M | $5.01M | $4.28M |
Avg Forecast | $72.75M | $70.36M | $65.87M | $63.44M | $63.76M | $59.51M | $48.61M | $4.94M | $40.56M | $34.94M | $31.21M | $5.28M | $2.78M | $19.51M | $18.00M | $5.65M | $12.31M | $10.58M | $9.29M | $10.62M | $7.27M | $5.64M | $5.98M | $7.32M | $5.90M | $3.26M | $2.31M | $1.97M | $1.82M | $1.48M |
High Forecast | $77.02M | $74.49M | $69.74M | $65.96M | $66.22M | $59.52M | $48.61M | $5.93M | $42.95M | $36.99M | $33.05M | $6.34M | $3.34M | $19.51M | $18.00M | $6.78M | $12.31M | $10.58M | $9.29M | $12.75M | $7.27M | $5.64M | $5.98M | $8.78M | $5.90M | $3.26M | $2.31M | $1.97M | $2.18M | $1.77M |
Low Forecast | $69.31M | $67.03M | $62.76M | $60.92M | $61.30M | $59.50M | $48.61M | $3.95M | $38.65M | $33.29M | $29.74M | $4.23M | $2.23M | $19.51M | $18.00M | $4.52M | $12.31M | $10.58M | $9.29M | $8.50M | $7.27M | $5.64M | $5.98M | $5.85M | $5.90M | $3.26M | $2.31M | $1.97M | $1.45M | $1.18M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.42% | 0.46% | 2.75% | 4.99% | 0.66% | 0.67% | 2.42% | 0.95% | 1.01% | 1.12% | 0.94% | 1.28% | 1.62% | 1.45% | 1.08% | 1.19% | 2.20% | 2.64% | 2.84% | 2.75% | 2.89% |
Forecast
ADMA Biologics EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 9 |
EPS | - | - | - | - | - | - | - | - | - | $0.01 | $-0.03 | $-0.06 | $-0.13 | $-0.10 | $-0.09 | $-0.18 | $-0.11 | $-0.16 | $-0.17 | $-0.19 | $-0.22 | $-0.23 | $-0.27 | $-0.29 | $-0.22 | $-0.23 | $-0.29 | $-0.28 | $-0.42 | $-0.55 |
Avg Forecast | $0.20 | $0.19 | $0.17 | $0.16 | $0.15 | $0.13 | $0.08 | $0.06 | $0.03 | $-0.01 | $-0.03 | $-0.04 | $-0.07 | $-0.08 | $-0.08 | $-0.09 | $-0.09 | $-0.14 | $-0.15 | $-0.17 | $-0.17 | $-0.19 | $-0.16 | $-0.11 | $-0.17 | $-0.21 | $-0.28 | $-0.29 | $-0.23 | $-0.28 |
High Forecast | $0.22 | $0.20 | $0.18 | $0.17 | $0.17 | $0.14 | $0.09 | $0.06 | $0.04 | $-0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.08 | $-0.08 | $-0.09 | $-0.09 | $-0.14 | $-0.15 | $-0.17 | $-0.17 | $-0.19 | $-0.16 | $-0.11 | $-0.17 | $-0.21 | $-0.28 | $-0.29 | $-0.18 | $-0.22 |
Low Forecast | $0.19 | $0.18 | $0.16 | $0.13 | $0.14 | $0.12 | $0.08 | $0.05 | $0.01 | $-0.01 | $-0.03 | $-0.05 | $-0.08 | $-0.08 | $-0.08 | $-0.09 | $-0.09 | $-0.14 | $-0.15 | $-0.17 | $-0.17 | $-0.19 | $-0.16 | $-0.11 | $-0.17 | $-0.21 | $-0.28 | $-0.29 | $-0.28 | $-0.33 |
Surprise % | - | - | - | - | - | - | - | - | - | -1.52% | 1.14% | 1.35% | 1.86% | 1.29% | 1.17% | 2.12% | 1.19% | 1.16% | 1.11% | 1.15% | 1.33% | 1.23% | 1.72% | 2.54% | 1.27% | 1.08% | 1.04% | 0.97% | 1.83% | 1.96% |
Forecast
ADMA Biologics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
FATE | Fate Therapeutics | $2.07 | $39.67 | 1816.43% | Hold |
XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
ANTX | AN2 Therapeutics | $1.23 | $8.75 | 611.38% | Buy |
INMB | INmune Bio | $4.76 | $22.00 | 362.18% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.50 | $6.00 | 300.00% | Buy |
AKBA | Akebia Therapeutics | $1.82 | $6.50 | 257.14% | Buy |
SANA | Sana Bio | $2.35 | $8.00 | 240.43% | Buy |
VXRT | Vaxart | $0.60 | $2.00 | 233.33% | Hold |
PLRX | Pliant Therapeutics | $12.85 | $39.71 | 209.03% | Buy |
STOK | Stoke Therapeutics | $11.27 | $30.60 | 171.52% | Buy |
ETNB | 89bio | $8.38 | $22.00 | 162.53% | Buy |
RCUS | Arcus Biosciences | $14.28 | $33.00 | 131.09% | Buy |
BCRX | BioCryst Pharmaceuticals | $7.49 | $16.00 | 113.62% | Buy |
MCRB | Seres Therapeutics | $0.73 | $1.25 | 71.23% | Buy |
CRBU | Caribou Biosciences | $1.98 | $3.00 | 51.52% | Buy |
CDTX | Cidara Therapeutics | $17.45 | $24.00 | 37.54% | Buy |
ATRA | Atara Biotherapeutics | $10.61 | $10.33 | -2.64% | Sell |
MDGL | Madrigal Pharmaceuticals | $329.24 | $315.75 | -4.10% | Buy |
ACLX | Arcellx | $87.22 | $83.00 | -4.84% | Buy |
ADMA | ADMA Biologics | $21.30 | $16.00 | -24.88% | Strong Buy |